You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

adult solid tumor

Showing 9976 - 10000 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cutaneous Neurofibroma Trial in New York (DPCP)

Not yet recruiting
  • Cutaneous Neurofibroma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Jun 24, 2022

Acral Melanoma, Mucosal Melanoma Trial in Seoul (Pembrolizumab, Vactosertib)

Not yet recruiting
  • Acral Melanoma
  • Mucosal Melanoma
  • Pembrolizumab, Vactosertib
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Jun 23, 2022

Physical Activity Trial in Ghent (physical activity)

Completed
  • Physical Activity
  • physical activity
  • Ghent, Belgium
    Ghent University
Nov 30, 2021

Chronic Spontaneous Urticaria, Recurrent Angioedema Trial in Germany (Dupilumab, Placebo)

Completed
  • Chronic Spontaneous Urticaria
  • Recurrent Angioedema
  • Marburg, Hessen, Germany
  • +5 more
Feb 1, 2022

Intrapartum and Postpartum Events in Adult Congenital Heart

Recruiting
  • Congenital Heart Disease
  • Pregnancy Complications
  • NT-proBNP
  • Rochester, Minnesota
    Mayo Clinic
Jan 31, 2022

Cancer Survivor Trial in New Brunswick (Questionnaire Administration, Telephone-Based Intervention)

Completed
Has Results
  • Cancer Survivor
  • Questionnaire Administration
  • Telephone-Based Intervention
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Oct 17, 2022

Pneumonia, Viral Trial in Italy, United States (Reparixin, Placebo)

Completed
  • Pneumonia, Viral
  • Washington, District of Columbia
  • +16 more
Jan 14, 2022

Hormone-refractory Prostate Cancer Trial (AMX-500)

Not yet recruiting
  • Hormone-refractory Prostate Cancer
  • (no location specified)
Aug 11, 2023

Diffuse Large B Cell Lymphoma Trial in Philadelphia (Nivolumab, IV, 240 mg)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Nivolumab, IV, 240 mg
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 3, 2023

Alzheimer's Disease Trial in Changsha (AD16 5mg?10mg?20mg?30mg?40mg?60mg?80mg, AD16 5mg?10mg?20mg?30mg?40mg?60mg?80mg)

Completed
  • Alzheimer's Disease
  • AD16 5mg、10mg、20mg、30mg、40mg、60mg、80mg
  • AD16 placebo 5mg、10mg、20mg、30mg、40mg、60mg、80mg
  • Changsha, China
    The Central South University Xiang Ya Hospital
Mar 14, 2023

Hematologic Malignancy Trial in Bologna

Recruiting
  • Hematologic Malignancy
    • Bologna, Italy
      Programma Dipartimentale Terapie Cellulari Avanzate
    Apr 17, 2023

    Patients With Resected Stage II Colon Cancer Trial in Dijon (mFOLFOX6)

    Recruiting
    • Patients With Resected Stage II Colon Cancer
    • Dijon, France
      Fédération Francophone de Cancérologie Digestive
    Oct 21, 2021

    Validation of Biomarker Assay

    Active, not recruiting
    • Healthy
    • Blood collection
    • Philadelphia, Pennsylvania
      Abramson Cancer Center of the University of Pennsylvania
    Jan 9, 2023

    Germ Cell Tumors, Testicular Tumors, Non Seminomatous Germ Cell Tumors Trial in Indianapolis, Philadelphia (Pembrolizumab)

    Terminated
    Has Results
    • Germ Cell Neoplasms
    • +6 more
    • Indianapolis, Indiana
    • +1 more
    Jul 7, 2022

    Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia Trial in Columbus (Health Promotion and Education, Medical

    Active, not recruiting
    • Acute Lymphoblastic Leukemia
    • +11 more
    • Health Promotion and Education
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Jul 24, 2023

    Prostate Cancer Trial in Canada, United States (Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation

    Unknown status
    Has Results
    • Prostate Cancer
    • Brachytherapy (100/110)
    • +2 more
    • Phoenix, Arizona
    • +169 more
    Nov 2, 2021

    CNS Tumors, CNS Tumor Trial in Saint Louis (Tc-99m tilmanocept)

    Recruiting
    • Central Nervous System Neoplasms
    • Central Nervous System Tumor
    • Tc-99m tilmanocept
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 28, 2022

    Checkpoint Inhibitor Response

    Active, not recruiting
    • NSCLC
    • +4 more
    • Breathprint analysis and patient-reported outcomes
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Feb 24, 2022

    Melanoma (Skin) Trial in Nice, Montpellier, Lille (Evaluation of cytokine production)

    Not yet recruiting
    • Melanoma (Skin)
    • Evaluation of cytokine production
    • Nice, Alpes-maritimes, France
    • +2 more
    Dec 5, 2022

    Breast Cancer, Breast Cancer Metastatic Trial in Spain (Niraparib 100 MG, Aromatase Inhibitors)

    Terminated
    • Breast Cancer
    • Breast Cancer Metastatic
    • Niraparib 100 MG
    • Aromatase Inhibitors
    • A Coruña, Spain
    • +9 more
    Jan 17, 2023

    Parkinson's Disease (PD) Trial in Australia, United States (ABBV-951)

    Enrolling by invitation
    • Parkinson's Disease (PD)
    • Birmingham, Alabama
    • +52 more
    Oct 17, 2022

    Cancer Cachexia Trial (OC514 (Low dose), OC514 (Mid dose), OC514 (High dose))

    Not yet recruiting
    • Cancer Cachexia
    • OC514 (Low dose)
    • +3 more
    • (no location specified)
    Feb 21, 2022

    Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders Trial in United States (Placebo,

    Completed
    • Sleep Apnea, Obstructive
    • +2 more
    • Placebo
    • Lemborexant 10 mg
    • Glendale, Arizona
    • +10 more
    Feb 15, 2022

    Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

    Recruiting
    • Deleterious BRCA1 Gene Mutation
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 23, 2022

    Prostate Cancer Trial in New York (177Lu-PSMA-617, Stereotactic Body Radiotherapy (SBRT))

    Active, not recruiting
    • Prostate Cancer
    • New York, New York
      Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    Nov 17, 2022